FDA Bans Certain Imports From Indian Drugmaker Wockhardt

Law360, New York (May 23, 2013, 4:04 PM EDT) -- The U.S. Food and Drug Administration on Wednesday blocked certain imports from India-based drugmaker Wockhardt Ltd. after inspections allegedly turned up violations of good manufacturing practices.

The so-called import alert affects medications that Wockhardt produces at a plant in the Indian city of Aurangabad, which sits about 200 miles east of Mumbai. Company executives predicted it will take months to have the ban lifted and that, in a worst-case scenario, they stand to lose $100 million in revenue, according to published reports.

Wockhardt has 14 manufacturing...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.